Table 3.

Dose modifications and discontinuations.

	n/N	%
Participants requiring dose reduction and/or discontinuation	45/61	73.8
Lenalidomide only dose reduction and/or discontinuation	12/61	19.7
Bevacizumab only dose reduction and/or discontinuation	6/61	9.8
Docetaxel only dose reduction and/or discontinuation	1/61	1.6
>1 medications requiring dose reduction and/or discontinuation	26/61	42.6
Participants requiring dose reduction for one or more medications	35/61	57.4
Lenalidomide dose reduction	34/61	55.7
Bevacizumab dose reduction	N/A	N/A
Docetaxel dose reduction	19/61	31.1
Participants requiring one or more medications discontinued	21/61	34.4
Lenalidomide discontinued	12/61	19.7
Bevacizumab discontinued	16/61	26.2
Docetaxel discontinued	1/61	1.6